The study aims to compare the effect of 2 different RA
treatments on cardiovascular health in patients who are considering a treatment
change. The study is recruiting patients who are only taking methotrexate and
are switching treatment due to a lack of improvement. The trial will randomize
participants to take a TNF inhibitor (Enbrel or Humira) in addition to their
Methotrexate or to take Triple Therapy (Methotrexate + Sulfasalazine +
Hydroxychloroquine). The study will provide you with all trial medications
(excluding Methotrexate) for the 6 month duration of the study.Study involvement requires 2 FDG-PET/CT scans
and 6 follow-up visits over a period of 6 months.
A typical study visit includes fasting blood work,
questionnaires, a physical exam, and a joint count. FDG-PET/CT visits require
•Visit 1 – Screening
•Visit 2 – Baseline, Week 0
•Visit 3 – Week 6
•Visit 4 – Week 12
•Visit 5 – Week 18
•Visit 6 – Week 24
Participants will receive $50 per study visit ($350 total) and free RA medication (excluding methotrexate) for the duration of the trial.
Study Identifier: 828509
Contact the research team to learn more about this study.